Search results
Showing 31 to 45 of 91 results for cholesterol
secondary prevention, as measured by smoking status, body mass index, cholesterol 85 years, had significant comorbidity, and were...
Alitretinoin for the treatment of severe chronic hand eczema (TA177)
Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.
This indicator covers the proportion of adults with diabetes who have received all 9 basic care processes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG13
Innovative Medicines Optimisation Clinic for PCSK9 inhibitors & Statin Intolerance
for PCSK9i and optimise their lipid therapy to enable achieving optimal cholesterol targets. Guidance the shared learning
appointment we advise how to complete the buccal swab and give advice on cholesterol management through lifestyle choices such as diet,...
Implementation of NICE TA393/394 in a tertiary Lipid Clinic - the first three years experience
who are at high or very high risk of CVD and Low density lipoprotein cholesterol (LDL-C) concentrations persistently above the...
(usually with medicines) : taking a statin or other medicine to manage your cholesterol. Your diabetes team can explain more about these...
through electronic primary care database searching is to search using total cholesterol or LDL‑C concentration. Currently, the entire...
This indicator covers the percentage of patients with type 1 diabetes who are aged over 40 years currently treated with a statin. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM142
Evidence-based recommendations on single incision laparoscopic cholecystectomy. This involves removing the gallbladder through a small cut, most often below the bellly button.
Re-engineering the Post-Myocardial Infarction Medicines Optimisation Pathway
A large proportion of those patients were also not achieving adequate cholesterol and blood pressure targets, which, in turn, might have...
Kidney conditions: CKD and lipid lowering therapies (IND231)
This indicator covers the percentage of patients with CKD, on the register, who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM213
Cardiovascular disease prevention: secondary prevention with lipid lowering therapies (IND230)
This indicator covers the percentage of patients with cardiovascular disease who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM212
This guideline covers the main risk factors linked with cardiovascular disease: poor diet, physical inactivity, smoking and excessive alcohol consumption. It aims to reduce the high incidence of cardiovascular disease. This, in turn, will help prevent other major causes of death and illness, such as type 2 diabetes and many cancers.
Cardiovascular disease prevention: primary prevention with lipid lowering therapies (IND229)
This indicator covers the percentage of patients with a cardiovascular disease risk assessment score of 10% or more who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM211